In a report released on November 27, Mara Goldstein from Mizuho Securities maintained a Buy rating on Autolus Therapeutics (AUTL – Research Report), with a price target of $12.00.
Mara Goldstein’s Buy rating for Autolus Therapeutics is based on a mix of recent strategic developments and the potential of the company’s product pipeline. Specifically, Goldstein notes the importance of Autolus Therapeutics’ submission of a Biologics License Application (BLA) for obe-cel in relapsed/refractory adult acute lymphoblastic leukemia (aALL) aligns with previous management projections. Additionally, the anticipation of long-term data from the pivotal FELIX trial at the American Society of Hematology (ASH) meeting and further data in the first half of 2024 supports the positive outlook.
Furthermore, Goldstein’s analysis recognizes the significant opportunity in the aALL market where treatment options are currently scarce. She also values the company’s exploration of obe-cel for autoimmune diseases, which could represent a competitive edge in the market. The financial stability of Autolus, underscored by its substantial cash reserves of approximately $256 million, further solidifies the Buy rating. Consequently, Goldstein maintains a $12 price target for Autolus Therapeutics, reflecting these combined factors.
In another report released on November 27, Wells Fargo also maintained a Buy rating on the stock with a $6.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.
Autolus Therapeutics (AUTL) Company Description:
Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm’s portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom.
Read More on AUTL:
- Autolus Therapeutics submits BLA to U.S. FDA for obecabtagene autoleucel
- Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
- Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023
- Autolus Therapeutics initiated with a Buy at Deutsche Bank
- Biotech Alert: Searches spiking for these stocks today
